Patients with newly diagnosed, unresectable, metastatic and measurable ASPS will also be eligible if they show clinical evidence of disease progression (including history and increasing physical symptoms); on-study documentation will include a physician’s rationale that supports evidence of clinical disease progression (i.e., increasing tumor pain) Have documented disease progression following at least 1 and no more than 2 prior systemic regimens for advanced disease (nonresectable or metastatic). Subjects must have received at least 1 gemcitabine- or 5-FU-containing regimen for advanced cholangiocarcinoma. Subjects who have received systemic adjuvant chemotherapy will be permitted provided there is documented disease progression during or within 6 months of completing the therapy. The patient must have experienced disease progression or intolerance as outlined above after treatment with 1 or more prior chemotherapies Elevation in tumor markers without radiographic evidence of disease progression is not satisfactory for progression on previous treatment Patients must have confirmed progression during or after treatment with either nivolumab or pembrolizumab. Confirmed progression is defined as: Progression on at least one prior systemic therapy or progression during an observation phase of no anti-cancer therapy within the prior 3 months; prior taxanes are allowed Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy Disease progression within 6 months after the last treatment. Prior ACT therapy should be completed, and residual disease documented by either radiographic progression or active disease observed on biopsy (i.e. hematologic or solid tumor malignancy must be deemed active by the treating investigator); the investigator may deem that the disease is active on the basis of a pre-treatment biopsy demonstrating viable tumor cells or clinical progression of disease (i.e. RECIST progression is not required) Documented disease progression within 6 months prior to study registration, as defined by RECIST criteria Received prior treatment with AZD9291 (osimertinib) or CO1686 (rociletinib) and experienced disease progression. Disease progression at study entry Must have shown disease progression according to RECIST, version 1.1, following prior chemotherapy for metastatic or surgically unresectable urothelial cancer. Subjects who received neoadjuvant or adjuvant chemotherapy and showed disease recurrence or progression according to RECIST, version 1.1, within 12 months of the last dose are considered to have received chemotherapy in the metastatic setting. These subjects will be referred to as chemo-refractory subjects. (Subjects who have shown disease progression according to RECIST, version 1.1 following prior treatment with anti-Programmed death-ligand 1 (anti PDL1/PD1) antibodies are also eligible) Objective, documented evidence of disease progression on study entry Participants must have evidence of disease progression within 12 months prior to study entry Prior chemoembolization of local ablative therapies are allowed, provided there is measurable disease outside of the area treated, or documented evidence of progression at the site of prior treatment Patient after progression with to imatinib at the dose of 400 mg as first line treatment. Resistance Progression is defined as a RECIST 1.1 and/or CHOI disease progression while receiving imatinib treatment Must have radiographic disease progression after at least 1 line of systemic cytotoxic therapy for metastatic disease or with progression within 12 months of completing adjuvant chemotherapy. All patients must have experienced disease progression on or after their most recent systemic therapy. Patients that have had prior treatment must show disease progression during or following the last treatment according to RECIST 1.1 criteria. Confirmed radiologic disease progression during or following recent treatment experienced disease progression during or after prior first-line regimen for metastatic disease Evidence of tumor progression on or after the last treatment regimen received and within 6 months prior to study enrollment Has MM defined by the IMWG criteria with evidence of disease progression and: At least one previous treatment for WM with either documented disease progression or no response (stable disease) to the most recent treatment regimen Participants must have documentation of a new or progressive lesion on a radiologic imaging study performed within 12 months prior to study enrollment (progression of disease over any interval is allowed) and/or new/worsening disease related symptoms within 12 months prior to study enrollment; this assessment is performed by the treating investigator; evidence of progression by RECIST criteria is not required Radiologic evidence of disease progression within 6 months prior to randomization. If the patient received other intervening therapy after documented disease progression, further disease progression must be documented after the completion of the intervening therapy INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Presence of disease progression on the most recent disease evaluation INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED AT AN OUTSIDE CLIA CERTIFIED LOCATION): Presence of disease progression on the most recent disease evaluation Patients must evidence of disease progression, either clinically or radiographically, within the 12 weeks prior to study enrollment, as determined by the investigator enrolling the patient on the study Must have evidence of progressive disease with biochemical (i.e. rising CA-125) and/or radiologic progression Documented disease progression per RECIST v.1.1 during or immediately after last therapy according to any of the aforementioned criteria. Radiologically confirmed disease progression Relapse or progression after at least 1 systemic therapy Patients in remission who are enrolled on another study where time to progression or disease free survival is a primary endpoint Disease progression (AD worse) in non-risk organs at any time during continuation treatment Documented disease progression following prior therapy, as assessed by the Investigator. Patients must have evidence of disease progression prior to enrollment Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease, or not be a candidate for therapy of proven efficacy for their disease due to an underlying physical condition Patients must have radiologic evidence of disease progression Documented progression to prior therapies: a) Cohort A: Disease progression following prior immune checkpoint blockade therapy; b) Cohort B: Progression or intolerance to at least 2 prior lines of standard therapy for unresectable or metastatic CRC; c) Cohort C: Disease progression following prior immune checkpoint blockade therapy. Evidence of disease progression at the time of enrollment Radiologically documented disease progression on previous osimertinib treatment. Radiologically documented disease progression on or after most recent antitumor therapy. Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomization Patients with disease progression prior to enrollment Patients must have recurrence or progression of their low-grade glioma after coming off treatment with AZD6244 on PBTC-029 or PBTC-029B, with or without having received additional anti-tumor therapy following discontinuation of AZD6244; the progression must be unequivocal and sufficient to warrant re-treatment in the opinion of the investigator; progression will be defined as either progressive disease (PD) that meets the study definitions of progressive disease by MRI or vision deterioration thought to be related to tumor in patients with optic pathway tumors Tumor progression after radiation Disease progression by IWG criteria since last therapy Progression of disease Adult patients stage IV lung cancer or melanoma receiving commercial supply immune checkpoint inhibitor therapy with progression of disease, and for whom an additional 4-6 weeks of current therapy (post-progression therapy) is acceptable as standard therapy Have evidence of radiographic disease progression with scan documenting progression occurring within 8 weeks of signing informed consent Patients must have experienced disease progression within 13 months prior to study registration or experienced intolerable side effects on a tyrosine kinase inhibitor. No progression is required for patients with anaplastic thyroid cancer. Documented failure to achieve at least PR with, or documented disease progression after, the most recent treatment regimen. Documented disease progression or intolerance to treatment either during or after treatment with most recent therapy Clinical or radiographic evidence of disease progression during treatment with PD-1 or PD-L1 inhibiting therapy\r\n* Note: Both the treating medical oncologist and radiation oncologist must be in agreement with determination of disease progression Progressive disease by RECIST 1.1 with or without symptoms within the last 12 months; NOTE: untreated patients with existing histologic diagnoses are eligible if progression can be demonstrated For the expansion cohort: patients must have had disease progression on alectinib (including patients who received alectinib as first-line treatment); subsequent anti-neoplastic therapy (including other ALK inhibitors or chemotherapy) after progression on alectinib is not permitted; Note: patients in the dose-finding portion of the study may have received other anti-neoplastic therapy after progression on alectinib Patients who have received previous treatment with T-DM1 and had systemic progression of disease while on it, are ineligible; patients receiving treatment with TDM1 whose only site of disease progression was brain are allowed to enroll in this trial Evaluation by the treating medical oncologist (or if systemic therapy is being given outside Stanford, by the Stanford consulting medical oncologist) must show:\r\n* The patient is expected to continue on immunotherapy for at least three more months\r\n* Imaging must show response, stable disease, or modest progression\r\n* If there is modest progression, the patient must be clinically stable in terms of performance status and overall disease-related symptoms Soft tissue disease progression as defined by RECIST 1.1. Patients must have evidence of disease progression and cannot be a candidate for surgical treatment or radiation\r\n* NOTE: Disease progression is defined as one of the following occurring within the 6 months prior to study entry:\r\n** At least a 20% increase in radiologically or clinically measurable lesions\r\n** Appearance of any new lesions or\r\n** Symptomatic and/or deterioration in clinical status Patients who were previously exposed to zydelig and experienced progression of disease Progressive disease: GIST has demonstrated progression as defined by RECIST v1.1 within the past 12 months; patients whose tumors do not meet this criterion, and have a diagnosis of NF1, may enroll on the NF1 natural history study (For cohort A): No limit on prior therapies for metastatic disease. (Relapse of disease within 6 months of adjuvant or neoadjuvant chemotherapy is considered 1 line of therapy for metastatic disease). (For cohort B): received at least one dose of an anthracycline-based NACT. Patients are eligible if therapy was discontinued due to disease progression or therapy intolerance. Patients with disease progression on anthracycline-based therapy should be evaluated by the surgical team. If the patient is deemed inoperable at the time of evaluation, the patient may continue to undergo protocol therapy with a goal of reduction in tumor size to become operable. If the patient is deemed at high risk of becoming inoperable by the surgical team based upon tumor size or location, the patient will be considered ineligible for study and will be recommended to go to surgery Must have radiographic disease progression after 1 line of systemic cytotoxic therapy for metastatic disease or with progression within 12 months of completing adjuvant chemotherapy Patients may be maintained on hormonal therapy provided there is clear evidence of tumor progression Chemotherapy refractory disease in aggressive NHL is defined as\r\n* Stable disease of =< 12 months or progressive disease as best response to most recent chemotherapy containing regimen\r\n* Disease progression or recurrence =< 12 months of prior autologous stem cell transplantation (SCT) Progression following standard combined modality treatment with radiation and temozolomide chemotherapy Received systemic multiple myeloma therapy post-relapse/progression; patients that received 1-2 cycles of salvage therapy, local radiation, and/or corticosteroids post-relapse/progression are eligible if there was no further disease progression following administration Patients must have progressive disease at study entry defined as one or more of the following three criteria that occurred while the patient was on androgen deprivation therapy; for patients enrolling on the basis of soft tissue or bone progression, the baseline scan must show progression relative to a comparison scan; if the comparison scan is not available, the baseline scan report must reference the previous scan to document progression Partial response (PR) as best response after at least 6 cycles and biopsy-proven residual disease or disease progression ? 12 months from initiation of therapy Disease progression by IWG Working Group or ICML criteria since last therapy Patients with SSc as defined by the American College of Rheumatology with diffuse cutaneous disease (except Group 5) at risk of disease progression An interval of at least 12 weeks from the completion of radiation therapy to registration unless there is unequivocal histologic confirmation of tumor progression There must be evidence of progression on or after last treatment regimen received and within 6 months of enrollment Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment Documented progression of disease on at least one 5-FU-based regimen and at least one GEM-based regimen for metastatic disease (progression during or within 3 months of the completion of adjuvant therapy is acceptable) Patient must have disease progression with abiraterone treatment In the opinion of the investigator and confirmed by the Millennium medical monitor, the participant may continue to benefit from treatment with ixazomib (eg, response to therapy or stable disease without evidence of disease progression). Subjects who have undergone at least six months of chemotherapy without radiologic progression of the tumor burden Patients must have refused or have evidence of intolerance to or progression on imatinib Patients must have biopsiable disease at the time of enrollment as biopsies after progression are required for participation Patients must be three or more months from the end of chemoradiotherapy or have biopsy or imaging consistent with disease progression Failure to respond to standard therapy, or for whom standard or curative therapy does not exist, or is not tolerable. a. Subjects enrolled in the Expanded Cohort should have no more than 3 prior systemic regimens with confirmed disease progression. If the subject is refractory or has disease progression within 6 months of the adjuvant treatment, then the previous treatment should be considered as the line of treatment rather than an adjuvant therapy. Patients must ? 12 weeks from radiotherapy, to minimize the potential for magnetic resonance imaging (MRI) changes related to treatment (pseudo progression) that might be misdiagnosed as true progression of disease, unless the patient fulfills criteria for early progressive disease by RANO. PHASE II DOSE EXPANSION IN NEWLY DIAGNOSED GBM: Patients must have completed standard radiation therapy with concurrent temozolomide (TMZ) within 5 (weeks) wks of enrollment and must not have evidence of progressive disease on post treatment imaging; progression can only be defined using diagnostic imaging if there is new enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line) or if there is unequivocal evidence of viable tumor on histopathologic sampling(e.g., solid tumor areas [i.e,> 70% tumor cell nuclei in areas], high or progressive increase in mindbomb homolog 1[MIB-1] proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor); Note: given the difficulty of differentiating true progression from pseudoprogression, clinical decline alone, in the absence of radiographic or histologic confirmation of progression, will not be sufficient for definition of progressive disease in the first 12 weeks after completion of concurrent chemoradiotherapy Patients must have a history of tumor progression or persistent disease or failure to achieve complete response following standard therapy No evidence of disease progression: defined as increase in tumor size of > 25% or new lesions Disease progression or intolerance to at least two prior Food and Drug Administration (FDA)-approved therapeutic regimens Symptomatic metastatic disease with signs of rapid progression per investigator’s clinical judgment Documented disease progression (as per RECIST v1.1) before study entry; for patients with osteosarcoma, this progression will be confirmed by central review on the basis of two CT scan or magnetic resonance imaging (MRI) obtained at less than 6 months in the period of 12 months prior to inclusion Evidence of progression of disease as defined by RECIST 1.1 (i.e. new disease sites or 20% growth of index lesions) within 6 months of registration Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy Patients with clear cell histology must have demonstrated: 1) progression on at least one prior anti-angiogenic agent unless intolerable; AND 2) progression on at least one agent that blocks the PD-1 pathway unless felt by the treating physician to be contraindicated (examples include but are not limited to: patients with autoimmune disease or patients requiring systemic steroids greater than 10 mg/day prednisone or its equivalent) or if they have been discontinued due to toxicity; prior rapalogues are allowed Subjects who experience a disease response per RECIST 1.1 criteria followed by subsequent progression will be required to have a post-treatment biopsy if feasible and safe Must have evidence of either RECIST 1.1 defined disease progression or stable disease 1 year after initiating nivolumab therapy Patient must not have clinical evidence of disease progression prior to the CD8+ memory T-cell infusion Unequivocal evidence of tumor progression by MRI Progression of disease must be documented prior to study entry Cutaneous T-cell lymphomas (mycosis fungoides, Sezary syndrome)\r\n* >= stage III\r\n* Disease progression >= 2 prior regimens, including at least one systemic therapy Progression or refractory disease to at least one regimen of therapy for metastatic disease in the breast and pancreatic cancer cohorts COHORT A: Patients must have progressive disease, defined as the presence of new or growing lesion(s) on radiologic imaging within 14 months of study enrollment and/or new/worsening disease related symptoms within 14 months of study enrollment; (progression according to RECIST v 1.1 criteria is not required) Willingness to forego additional therapy until evidence of disease progression Patients with evidence of disease progression post SCT at the time of consideration for the study enrollment will not be included Evidence of progression or lack of response following at least 1 prior treatment for indolent lymphoma Multifocal progression or involvement of the leptomeninges Patients must have had disease progression on or following their most recent treatment regimen or on presentation for the first time with metastatic disease For NSCLC participants in parts C, D, and F: if currently receiving gemcitabine or pemetrexed (single-agent or in combination with another therapy), a participant may continue to receive 1 of these 2 therapies provided that extracranial disease is stable for at least 6 weeks and CNS disease progression has occurred while on this therapy. Evidence of disease progression defined by progressive VS growth during the previous 12 months (> 20% increase in volume, as clinically determined) in all patients; usually patients with disease progression proceed to microsurgical resection, however for those patients who are at increased risk for surgical complications (e.g., deafness, lower cranial nerve injury, facial weakness) or who refuse surgery, enrollment in the study may be the best clinical option Disease progression or relapse prior to HPC infusion Documented disease progression on or after prior systemic treatment administered for the advanced disease including CYP 17 inhibitors and/or androgen-pathway inhibitors (i.e. abiraterone and/or enzalutamide when available) and no more than one line of chemotherapy for the advanced disease, or patients who were ineligible (unfit) to receive chemotherapy. Disease progression defined as increasing serum PSA (per PCWG3), radiological progression or ? 2 new bone lesions. (Chemical castration is required unless surgically orchiectomized.) Participants must have completed 3 cycles of a bortezomib-based induction regimen (as defined by current NCCN guidelines) and have no evidence of disease progression as defined by IMWG criteria. Received either IPI-145 or ofatumumab while participating in study IPI-145-07 and experienced radiologically-confirmed disease progression Prior radiation performed to areas of measurable disease ? four weeks of study entry unless there is documented evidence of disease progression. Has had documented disease progression on or within 60 days after completion of the last therapy. Must have documentation of no evidence of disease progression of the tumor during or after completion of first line systemic anti-cancer therapy Patients must have completed standard radiation therapy with concurrent TMZ and must not have evidence of progressive disease on post treatment imaging. Progression can only be defined using diagnostic imaging if there is new enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line) or if there is unequivocal evidence of viable tumor on histopathologic sampling (e.g., solid tumor areas [i.e, > 70% tumor cell nuclei in areas], high or progressive increase in MIB-1 proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor). Note: Given the difficulty of differentiating true progression from pseudoprogression, clinical decline alone, in the absence of radiographic or histologic confirmation of progression, will not be sufficient for definition of progressive disease in the first 12 weeks after completion of concurrent chemoradiotherapy. (For Stage 1: Post-chemoradiation group only) Well-differentiated NET group: Disease progression while on/or after the last treatment, and this progression must have been observed within 6 months prior to start of study treatment (i.e. maximum of 24 weeks from documentation of progression until study entry). Disease must show evidence of radiological disease progression based on scans performed not more than 12 months apart. The subject must have stable disease after treatment of radiation with concurrent chemotherapy or in case of progression that the disease is controlled with another treatment type For subjects with glioma, specific inclusion criteria are as follows:\r\n* The disease should be recurrent or transformed glioma; subjects must not have had prior surgery (biopsy allowed) or radiation therapy within 3 weeks of enrollment\r\n* There must be an enhancing component of disease, as evaluated on pre-treatment magnetic resonance imaging (MRI)\r\n* For patients with World Health Organization (WHO) grade III or IV glioma and progressive disease < 12 weeks after completion of chemoradiotherapy, progression can be defined by the following set of criteria:\r\n** New enhancement outside of the radiation field (beyond the high-dose region or 80% isodose line)\r\n** If there is unequivocal evidence of viable tumor on histopathologic sampling (e.g., solid tumor areas. i.e., > 70% tumor cell nuclei in areas), high or progressive increase in MIB-1 proliferation index compared with prior biopsy, or evidence for histologic progression or increased anaplasia in tumor);\r\n** Note: Given the difficulty of differentiating true progression from pseudoprogression, clinical decline alone, in the absence of radiographic or histologic confirmation of progression, will not be sufficient for definition of progressive disease in the first 12 weeks after completion of concurrent chemoradiotherapy\r\n* For patients with WHO grade III or IV glioma and progressive disease >= 12 weeks after completion of chemoradiotherapy, progression can be defined by the following set of criteria:\r\n** New contrast-enhancing lesion outside of radiation field on decreasing, stable, or increasing doses of corticosteroids\r\n** Increase by >= 25% in the sum of the products of perpendicular diameters between the first post-radiotherapy scan, or a subsequent scan with smaller tumor size, and the scan at 12 weeks or later on stable or increasing doses of corticosteroids\r\n** For patients receiving antiangiogenic therapy, significant increase in T2/fluid attenuated inversion recovery (FLAIR) non-enhancing lesion may also be considered progressive disease; the increased T2/FLAIR must have occurred with the patient on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy and not be a result of comorbid events (e.g., effects of radiation therapy, demyelination, ischemic injury, infection, seizures, postoperative changes, or other treatment effects)\r\n** Note: Clinical deterioration alone is not attributable to concurrent medication or comorbid conditions is sufficient to declare progression on current treatment but not for entry onto a clinical trial for recurrence\r\n* For patients with WHO grade II glioma progression is defined by any one of the following:\r\n** Development of new lesions or increase of enhancement (radiological evidence of malignant transformation)\r\n** A 25% increase of the T2 or FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared with baseline scan or best response after initiation of therapy, not attributable to radiation effect or to comorbid events All subjects must have documented disease progression during or after their last antimyeloma therapy Disease progression following radiation and TMZ For metastatic disease to lung, primary tumor needs to be controlled (no evidence of progression on imaging for at least 2 months) Patients must have at least ONE of the following:\r\n* Recurrent/progressive disease at any time prior to enrollment - regardless of response to frontline therapy\r\n* Refractory disease: persistent sites of disease (after less than a partial response to frontline therapy, following a minimum of 4 cycles of induction therapy) AND patient has never had a relapse/progression\r\n* Persistent disease: persistent disease after achieving at least a partial response to frontline therapy after a minimum of 4 cycles of induction therapy and patient has never had a relapse/progression Patients who are initially rendered NED or have MRD following standard therapy but exhibit disease progression prior to initiation of vaccination Patients must have progression after prior treatment with Enza at any point in the disease course (pre- or post-chemotherapy) Documented disease progression at study entry A single dose of a platinum doublet discontinued due to intolerability without evidence of disease progression is permitted Participants must have shown unequivocal evidence of tumor progression. Disease progression during or after the last treatment regimen and within 6 months before study entry. Patients must have completed 3 cycles of R-CHOP with no evidence of disease progression Registration within 42 days of evidence of disease progression Disease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC. Progression of systemic disease at Screening Phase 1: Subjects who have disease progression after treatment with available therapies. Achieved less than a partial response (1 year after completing adjuvant therapy for Stage I-IIIA disease and no systemic therapy for the recurrent disease Progression of disease after last therapy demonstrated by RANO criteria Patients who have disease progression prior to completion of intended frontline therapy, including patients demonstrating disease progression after interval cytoreduction Previous systemic chemotherapy is permitted if administered as induction treatment (=< 2 cycles) before definitive chemoradiotherapy for early stage disease and there is no evidence of tumor progression during or after treatment completion Have evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria within 3 months prior to study enrollment; if the patient was receiving a prior line of systemic therapy, he/she should have evidence of disease progression on that line of treatment prior to enrollment Relapsed or refractory disease. Relapse is defined as progression of disease after an initial response to previous treatment, more than 60 days after cessation of treatment. Refractory disease is defined as less than (<) 25 percent (%) reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment Patients who have disease progression during, or after, receiving abiraterone treatment in any setting. Patients must have documented disease progression while on Arm 1 of this protocol; the follow-up tumor assessment form documenting disease progression must be submitted to Southwestern Oncology Group (SWOG) prior to Step 3 Crossover Registration Subjects must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced or metastatic disease Patients must have a history of tumor progression or persistent disease or failure to achieve complete response following standard therapy Subjects must have completed or had disease progression on at least one prior line of disease-appropriate therapy or not be candidates for therapy of proven efficacy for their disease Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over. If not clinically feasible, discussion with Sponsor is required Patients must have documentation of a new or progressive lesion on a radiologic imaging study performed within 6 months prior to study enrollment (progression of disease over any interval is allowed) and/or new/worsening disease related symptoms within 6 months prior to study enrollment; note: this assessment will be performed by the treating investigator; evidence of progression by RECIST criteria is not required Patients must have central lab confirmation of tumour T790M status from a biopsy taken after disease progression on the most recent treatment regimen. Only patients with T790M+ will be included in the study Evidence of tumor progression by MRI scan following radiation therapy or following the most recent anti-tumor therapy; note: patients who have had surgical treatment at recurrence are eligible if they had a resection with measurable residual disease on postoperative imaging or if there is imaging evidence of disease progression as compared to the first postoperative scan The participant received combination chemotherapy prior to disease progression. Patients are eligible upon progression after definitive local treatment (usually concurrent chemoradiation) if they are not candidates for salvage surgery or re-irradiation; patients are also eligible after progression on first line chemotherapy for recurrent disease Disease progression within 60 days of discontinuation from most recent therapy Disease progression on or after pemetrexed and cis- or carboplatin Disease progression following therapy with erlotinib, afatinib, or gefitinib Patients must be three or more months from the end of chemoradiotherapy or have biopsy or imaging consistent with disease progression Disease progression at study entry Patients must have documentation of a new or progressive lesion on a radiologic imaging study performed within 6 months prior to study enrollment (progression of disease over any interval is allowed) and/or new/worsening disease related symptoms within 6 months prior to study enrollment; note: this assessment will be performed by the treating investigator; evidence of progression by RECIST criteria is not required Documented disease progression after a platinum based chemotherapy in patients for whom administration of taxanes and anthracyclines is not planned. Progression must fulfill one of the following criteria: Disease progression on or within 60 days of completion of the last therapy Subject has disease progression by at least one of the following: Soft tissue disease progression as defined by RECIST 1.1 May have previously received lapatinib as part of a regimen in the perioperative or metastatic setting with evidence of progression of disease; washout period for lapatinib of 14 days For the dose-finding phase, patients may have stable disease OR progression of disease on the most recent treatment; for the expansion phase, patients must also have stable disease OR progression of disease on the most recent treatment; progression of disease is defined as new or worsening disease on objective imaging; progression or disease includes recurrence diagnosed while on adjuvant letrozole or exemestane Patients must have, in the opinion of the investigator, clinical complete response or partial response and have no clinical evidence of disease progression on the post treatment scan or rising CA-125 level, following completion of this chemotherapy course. Patients with stable disease on the post-treatment scan at completion of first line platinum-containing therapy are not eligible for the study. Stable disease or progressive disease on the post-treatment scan or clinical evidence of progression at the end of the patient's first line chemotherapy treatment. Concurrent use of somatostatin analogs (SSTa) is allowed, provided that the patient is on a stable dose for at least two months and progressive disease on somatostatin analog has been documented; progression on octreotide is required for patients with tumors arising in the midgut Anatomic imaging (CT or MRI) of all sites of disease along with chest CT at baseline and restaging for all patients will be done to allow for assessment of RECIST progression. RECIST progression will determine progressive disease regardless of other imaging. Patient must have documented disease progression, and date of last documented disease progression must be within 12 months from date of randomization Concurrent somatostatin analogues are allowed provided that the patient \r\n* Has been on a stable dose (+/- 10mg) for 8 weeks and \r\n* Has documented disease progression on that dose Relapse or progression after at least 1 systemic therapy Less than 2 years between last therapy and progression (e.g. most recent progression free interval < 2 years) Minimum of 3 months of maintenance therapy prior to disease progression Must have documented disease progression during or after their last anti-myeloma therapy. Patients with other systemic illness, or have not recovered adequately from their primary treatment or who have evidence of progression of their current cancer prior to therapy that, in the investigator’s opinion, would preclude their inclusion Progression following prior ofatumumab-based therapy Gynecologic Cancer Intergroup (GCIG)-defined CA125 progression and absence of disease upon imaging or small-volume asymptomatic disease upon imaging and who have progressed following one, two or three lines of chemotherapy for recurrent disease Permanent discontinuation of GSK2110183 in the parent study due to toxicity or disease progression. Concurrent somatostatin analogues are allowed provided that patients 1) have been on stable doses x 8 weeks and 2) have documented disease progression on that dose Participants must have met all criteria to be enrolled on the main protocol for receipt of neratinib; at the time of enrollment on the extension phase for cohorts 1 and 3, patients must have experienced progression of non-CNS disease by RECIST 1.1 criteria Clinical progression of symptoms with any radiographic progression on MRI within 21 days prior to registration (any progression in size or enhancement on MRI along with worsening symptoms, will be defined as progression prior to enrollment); radiographic progression is defined as any increase in tumor size (in axial or sagittal images) or progressive contrast enhancement and abnormal T2/FLAIR signal by MRI Disease progression prior to randomization Require radiation therapy for palliation of symptoms or to prevent local progression of disease and associated complications and/or symptoms from metastases Permanent discontinuation of GSK1120212 in the parent study due to toxicity or disease progression. In order to prevent registering patients with pseudo progression rather than true disease progression, patients must not have received any form of cranial radiation within 12 weeks of study entry; NOTE: patients who have received cranial radiation within 12 weeks of study entry will be allowed to register to trial only if either progressive disease is confirmed via biopsy or there is a new area of enhancement consistent with recurrent tumor outside the radiation field (defined as the region outside the high-dose region or 80% isodose line) No evidence of relapse or progression of underlying disease (molecular evidence of relapse/progression or mixed chimerism is permitted) Biochemical or radiologic documentation of disease progression within the last 12 months prior to enrollment Permanent discontinuation of GSK2118436 in the parent study due to toxicity or disease progression COHORT 1 AND ACINIC CELL CARCINOMA PATIENTS IN COHORT 2 ONLY: Patients must have documentation of a new or progressive lesion on a radiologic imaging study performed within 6 months prior to study enrollment (progression of disease over any interval is allowed) and/or new/worsening disease related symptoms within 6 months prior to study enrollment; Note: this assessment will be performed by the treating investigator; evidence of progression by RECIST criteria is not required Patients who have ASM with eosinophilia and known positivity for the FIP1L1-PDGFR? fusion unless they have demonstrated relapse or disease progression on prior imatinib therapy Cutaneous T-cell lymphomas (mycosis fungoides, Sezary syndrome)\r\n* >= Stage III\r\n* Disease progression >= 2 prior regimens, including at least one systemic therapy Evidence of relapse or progression of disease after transplantation Having documented disease progression on enzalutamide defined by 1 or more of the following criteria: Predicted not to have significant clinical progression at 4 months Completion of at least 1 cycle of treatment with ibrutinib and confirmed evidence of disease progression or refractoriness to treatment or Evidence of disease progression at study entry. Radiologic documentation of disease progression measurable disease at screening and documented progression within the past 6 weeks No response or disease progression ? 24 months from start of last previous therapy Patients must have documented disease progression after receiving at least one prior therapeutic regimen (e.g. pralatrexate, romidepsin, bexarotene, vorinostat) Progression of disease despite androgen ablation shown by objective, documented evidence of disease progression (excluding PSA). Objective documented evidence of disease progression at study entry Disease progression following radiation & TMZ Subjects with a history of prior radiotherapy are eligible if they meet the following parameters: Prior to study treatment administration, must be ? 21 days post-therapy and have recovered from all toxicities; must have evidence of measurable disease outside the radiation fields or radiologically confirmed progression of disease; must not have had > 25% of their functional bone marrow irradiated. Must have radiologically measureable disease, a life expectancy > 12 weeks, and adequate organ function. Progression was documented, Documented disease progression during or following most first line therapy for advanced disease Evidence of disease progression on neoadjuvant chemo T Disease progression despite standard therapies Subjects must have received one or more prior systemic therapies for this disease, with disease progression or intolerable toxicity precluding further therapy with prior regimen(s) Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease, or not be candidates for therapy of proven efficacy for their disease. Has evidence of disease progression under Protocol 8400-401. Objective evidence of disease progression on study entry Patient must have measurable disease per RECIST 1.1 presented after tumour biopsy for the late disease progression Patients must have completed or had disease progression on at least one prior line of disease-appropriate therapy for metastatic disease, or not be candidates for therapy of proven efficacy for their disease Prior to registration, patients must have achieved clinical benefit with crizotinib monotherapy and subsequently have systemically progressed; clinical benefit is defined as having stable disease on crizotinib monotherapy for at least 90 days or achieving a confirmed partial or complete response; systemic progression is defined as progressive disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, excluding progression based on brain/CNS metastases alone Patients must have experienced disease recurrence or progression during or after prior treatment with one or more prior standard systemic therapies; Histologically or cytologically confirmed high-grade metastatic sarcoma that has been stable on 6-12 cycles of one chemotherapeutic regimen (cytotoxic or biologic) although a change in chemotherapy is allowed if it is a result of toxicity/tolerability rather than progression; a patient must not have evidence of progression at any time while on chemotherapy in order to be eligible for this trial experienced no progression of disease per the irRC1 Patients must have evidence of progression of disease during or after last treatment Documented evidence of disease progression during 6 month period prior to the time of enrollment Participants who developed disease progression/ requiring other anti-tumor therapy while in the parent protocol Disease progression in the past 14 months Prior radioactive iodine must have been completed at least 6 months prior to registration, or there must be documented disease progression since such therapy if it was within 6 months; sites that have received EBRT must have disease progression post-EBRT to be used as sites of measurable disease Progressive disease defined as one or more of the following three criteria (Note: subjects who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen): There is progression of disease documented by RECIST 1.1 Patients must show evidence of objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1 on scans within the 6 month period immediately preceding enrollment; both scans used to determine disease progression should have been obtained within this 6-month period Patients with newly diagnosed, unresectable, metastatic, and measurable ASPS who show clinical evidence of disease progression (including history and increasing physical symptoms) will also be eligible; on-study documentation will include a physician’s rationale that supports evidence of clinical disease progression (i.e., increasing tumor pain) Phase 1: Subjects who have disease progression after treatment with available therapies. All patients must have evidence of progressive disease on study entry.Previously untreated patients who are not chemotherapy candidates on Arm 2 may have advanced disease (without clear progression). There is no upper limit on the number of prior treatments provided that all inclusion criteria are met and exclusion criteria are not met. Must have metastatic, progressive, castrate-resistant prostate cancer (CRPC) with radiographic evidence of disease that has continued to progress radiographically or biochemically (rising prostate-specific antigen [PSA] levels on successive measurements) despite adequate androgen-deprivation therapy; if patients had been on flutamide, disease progression is documented 4 weeks or more after withdrawal; for patients on bicalutamide or nilutamide disease progression is documented 6 or more weeks after withdrawal; flutamide, nilutamide and bicalutamide disease progression requirements only apply to patients who have been on these drugs for at least the prior 6 months Prior chemoembolization, radioembolization, radiofrequency ablation (RFA) or other local ablative therapies are permissible if >= 6 weeks from procedure with evidence of progression or new metastatic disease, if applicable Subjects must have documented disease progression prior to enrolling into the study Part II: Postmenopausal women with locally ABC or MBC whose disease has progressed during or after treatment with an AI. Participants who discontinued the AI for toxicity rather than completion of regimen or for disease progression are not eligible Evidence of disease progression, as determined by the investigator Confirmed evidence of disease progression from immediately prior MM therapy or refractory to the immediately prior treatment. Progression of solid tumors/lymphomas: Patients demonstrating clear tumor progression 4 weeks after receiving DLI will not be eligible to receive additional DLI Measurable disease per the RECIST criteria. For disease occurring in previously irradiated field, there must be confirmed progression prior to the date registration and more than three months after completion of radiotherapy Patients with documented disease progression on salvage chemotherapy Patients must have refractory disease, disease relapse or progression after at least two prior systemic chemotherapy or immunotherapy regimens\r\n* Note: Exceptions may be made if a patient is deemed unfit for first-line salvage therapy by the treating physician; such cases should be clearly documented Patients with uncontrollable progression of extra-thoracic disease will be excluded from study MM that is refractory to the most recent treatment regimen. Refractory is defined as ? 25% response to therapy, or progression during therapy, or progression on or within 60 days after completion of therapy. Objective evidence of disease progression on study entry progression of disease at the time of Enrollment And for Treatment Period 2 only: 1) Patients participating in Treatment Period 1 must have had disease progression after receiving at least 4 weeks of progestin therapy or 2) Patients must be determined as PrR negative status at Screening. Dose Confirmation Cohort A (DC-A) only: Currently receiving enzalutamide as most recent systemic therapy for mCRPC and have experienced PSA progression by PCWG2 criteria in the absence of radiographic and/or clinical progression. Patients may or may not have experienced prior progression on abiraterone. Evidence of disease progression that would necessitate a treatment in the next 2 weeks Evidence of disease progression or metastatic disease during or following definitive local therapy documented in the 10- to 12-week post-definitive local therapy scans Failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen For cohort 1 only: evidence of disease progression =< 14 months prior to registration according to RECIST 1.1, as confirmed by the site study principal investigator (PI) Well differentiated, low, intermediate, or high-grade, gastrointestinal mid-gut (arising from the lower jejunum, ileum, appendix, cecum, and proximal colon) NET with documented disease progression within 6 months prior to start of study treatment and evidence of radiographic disease progression based on scans performed not more than 15 months apart. Patients may have received 1 or more prior lines of anticancer therapy, such as somatostatin analogues, targeted agents, or liver-directed intra-arterial therapy, but are NOT eligible if they have received prior systemic cytotoxic chemotherapy or peptide receptor radionuclide therapy (PRRT). If receiving an antiandrogen as part of first-line hormonal therapy, must have shown progression of disease off the antiandrogen prior to enrollment Documented disease progression during or immediately after last therapy according to any of the aforementioned criteria. Disease progression within 12 months prior to study enrollment. They show evidence of disease progression during or within 12 months of the end\n of adjuvant ET. Time of disease progression.